WO2011146819A3 - METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES - Google Patents

METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES Download PDF

Info

Publication number
WO2011146819A3
WO2011146819A3 PCT/US2011/037308 US2011037308W WO2011146819A3 WO 2011146819 A3 WO2011146819 A3 WO 2011146819A3 US 2011037308 W US2011037308 W US 2011037308W WO 2011146819 A3 WO2011146819 A3 WO 2011146819A3
Authority
WO
WIPO (PCT)
Prior art keywords
integrin
treatment
methods
mediated
compositions
Prior art date
Application number
PCT/US2011/037308
Other languages
French (fr)
Other versions
WO2011146819A2 (en
Inventor
Anne M. Whalen
Jane Staunton
Janine Steiger
Amy B. Wilson
Yang Wu
Original Assignee
Dmd Therapies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dmd Therapies, Llc filed Critical Dmd Therapies, Llc
Publication of WO2011146819A2 publication Critical patent/WO2011146819A2/en
Publication of WO2011146819A3 publication Critical patent/WO2011146819A3/en
Priority to IL223095A priority Critical patent/IL223095A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Abstract

The invention features compositions, methods, and kits useful for the treatment of diseases mediated by NF-κΒ and diseases suppressed by α7 integrin.
PCT/US2011/037308 2010-05-20 2011-05-20 METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES WO2011146819A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL223095A IL223095A0 (en) 2010-05-20 2012-11-18 Methods and compositions for treatment nf-kb-mediated and a7 integrin-suppressed diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34674010P 2010-05-20 2010-05-20
US61/346,740 2010-05-20

Publications (2)

Publication Number Publication Date
WO2011146819A2 WO2011146819A2 (en) 2011-11-24
WO2011146819A3 true WO2011146819A3 (en) 2012-05-10

Family

ID=44992357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/037308 WO2011146819A2 (en) 2010-05-20 2011-05-20 METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES

Country Status (2)

Country Link
IL (1) IL223095A0 (en)
WO (1) WO2011146819A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105560233B (en) * 2015-12-25 2018-11-20 东北制药集团沈阳第一制药有限公司 A kind of medical composition and its use of jamaicin and fenofibrate

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140330022A1 (en) * 2012-01-05 2014-11-06 Kowa Company, Ltd. Collateral blood circulation development promoter
ITRM20120550A1 (en) * 2012-11-09 2014-05-10 Ist Fisioterap Ospitalroma INTEGRINE INHIBITOR FOR TREATMENT OR PREVENTION OF CANCER.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003019144A2 (en) * 2001-08-27 2003-03-06 Biswas Debajit K METHODS AND COMPOSITIONS FOR SCREENING, DIAGNOSING, OR TREATING NF-λB RELATED DISEASE
US20070270455A1 (en) * 2005-07-20 2007-11-22 Gudkov Andrei V INHIBITION OF NF-kB
US20080187595A1 (en) * 2005-08-19 2008-08-07 Andreas Jordan Method For Carrying Therapeutic Substances Into Cells
US20090004658A1 (en) * 2007-04-30 2009-01-01 Jianhua Luo Integrin alpha 7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma
US20100069302A1 (en) * 2007-07-18 2010-03-18 Stefan Krueger Specific therapy and medicament using integrin ligands for treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003019144A2 (en) * 2001-08-27 2003-03-06 Biswas Debajit K METHODS AND COMPOSITIONS FOR SCREENING, DIAGNOSING, OR TREATING NF-λB RELATED DISEASE
US20070270455A1 (en) * 2005-07-20 2007-11-22 Gudkov Andrei V INHIBITION OF NF-kB
US20080187595A1 (en) * 2005-08-19 2008-08-07 Andreas Jordan Method For Carrying Therapeutic Substances Into Cells
US20090004658A1 (en) * 2007-04-30 2009-01-01 Jianhua Luo Integrin alpha 7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma
US20100069302A1 (en) * 2007-07-18 2010-03-18 Stefan Krueger Specific therapy and medicament using integrin ligands for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. POCH ET AL.: "Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves", JOURNAL OF PHARMACOLOGICAL METHODS, vol. 4, 1980, pages 179 - 188 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105560233B (en) * 2015-12-25 2018-11-20 东北制药集团沈阳第一制药有限公司 A kind of medical composition and its use of jamaicin and fenofibrate

Also Published As

Publication number Publication date
WO2011146819A2 (en) 2011-11-24
IL223095A0 (en) 2013-02-03

Similar Documents

Publication Publication Date Title
WO2011047146A3 (en) Methods of affinity maturing antibodies
AU2016219704A1 (en) Anti-Notch1 antibodies
WO2014028461A3 (en) Treatment and diagnosis of melanoma
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
WO2012118903A3 (en) Sclerostin and dkk-1 bispecific binding agents
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2011119777A3 (en) Compositions and methods for treatment of neurodegenerative disease
WO2012173846A3 (en) Peptidomimetic macrocycles
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2013034979A3 (en) Crystalline forms of cabazitaxel
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
HK1164304A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
WO2013164839A3 (en) Amorphous form of apixaban, process of preparation and compositions thereof
WO2012112674A3 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
WO2012129299A3 (en) Medical instruments and methods for fabricating same
WO2012149334A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
WO2013120022A3 (en) Treatment of hypoglycemia
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
WO2012037116A3 (en) Genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
WO2012017321A3 (en) Treatment for dyslipidemia
WO2013155338A8 (en) Substituted benzamides and their uses
WO2013023059A3 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
WO2012109567A3 (en) Treatment of angiogenesis disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 223095

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2013511380

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 11784309

Country of ref document: EP

Kind code of ref document: A2